Rodriguez-Segade S, de la Peña C A, Tutor J C, Paz J M, Fernandez M P, Rozas I, Del Río R
Department of Biochemistry (Faculty of Pharmacy), University of Santiago de Compostela, Spain.
Clin Chim Acta. 1989 May 15;181(2):175-81. doi: 10.1016/0009-8981(89)90185-x.
Valproic acid therapy is known to be associated with carnitine deficiency in adult as well as young epileptic patients. In a study of the possible existence of such side-effects with other anticonvulsants, 76.5% of adult patients treated with valproate were deficient in serum free carnitine, with acylcarnitine levels significantly higher than in controls (p less than 0.01), while the carnitine deficiency rate in a group of patients treated with anticonvulsants other than valproate was 21.5%. Since in clinical practice only about one fifth of patients are treated with valproate, this means that about 15% of epileptics are carnitine deficient because of valproate treatment and 17% because of other anticonvulsants. The mechanisms and clinical and biological consequences of the carnitine deficiency associated with antiepileptic drugs other than valproate are not known.
已知丙戊酸疗法在成年及年轻癫痫患者中均与肉碱缺乏有关。在一项关于其他抗惊厥药物是否存在此类副作用的研究中，接受丙戊酸盐治疗的成年患者中有76.5%血清游离肉碱缺乏，酰基肉碱水平显著高于对照组（p小于0.01），而接受丙戊酸盐以外抗惊厥药物治疗的一组患者的肉碱缺乏率为21.5%。由于在临床实践中只有约五分之一的患者接受丙戊酸盐治疗，这意味着约15%的癫痫患者因丙戊酸盐治疗而肉碱缺乏，17%因其他抗惊厥药物而肉碱缺乏。与丙戊酸盐以外的抗癫痫药物相关的肉碱缺乏的机制以及临床和生物学后果尚不清楚。
